PTO/SB/08B (04-03)
Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 1 of 1

Complete if Known	
Application Number	09/423,100
Filing Date	December 11, 2000
First Named Inventor	Gan, Zhong-Ru
Art Unit	1647
Examiner Name	Nichols, Christopher J.
Attorney Docket Number	020167-000120US

CONSIDERED; DO NOT PRINT.

U.S. PATENT DOCUMENTS

Examiner	Cite No.[1]	Document Number: Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CJN	AA	US-5,422,110	06/06/1995	Potter et al.	
CJN	AB	US-SN 10/054,873	n/a	Gan	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]	Number[4]	Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
CJN	AC	EP	0 645 454	A2	03/29/1995	Lunin *et al.*		
CJN	AD	WO	98/23868	A1	08/08/1998	G.D. Searle & Co		
CJN	AE	CA	1,341,211		03/27/2001	Hoechst Aktiengesellschaft		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[7]
CJN	AF	~~BIOSIS DATABASE, Accession number 100407207026~~. Samuelsson *et al.*, 1994, "Enhanced *in vitro* refolding of insulin-like growth factor I using a solubilizing fusion partner," *Biochemistry* 33(14):4207-4211 (abstract)	
CJN	AG	~~BIOSIS DATABASE, Accession number PREV199700706120~~. Klappa *et al.*, 1997, "Interactions between protein disulphide isomerase and peptides," *European Journal of Biochemistry* 248(1):37-42 (abstract)	

Examiner Signature		Date Considered	9/11/2003

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO SB 08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	09/423,100
Filing Date	December 11, 2000
First Named Inventor	Gan, Zhong-Ru
Art Unit	1647
Examiner Name	~~Saoud, Christine J.~~
Attorney Docket Number	020167-000120US

U.S. PATENT DOCUMENTS

Examiner	Cite No.[1]	Document Number: Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GN	AA	US-5,473,049	12/05/1995	Obermeier, et al.	
GN	AB	US-5,358,857	10/25/1994	Stengelin, et al.	
GN	AC	US-5,559,128	09/24/1996	Chakravarty, et al.	
GN	AD	US-5,719,021	02/17/1998	Inouye	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]	Number[4]	Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
GN	AE	EP	0 055 945		07/14/1982	Goeddel, et al.		☐
	~~AF~~	~~EP~~	~~0 347 781 B1~~		~~12/27/1989~~	~~Dörschug, et al.~~		☐

Examiner Signature	GNiebel	Date Considered	3/6/2003

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] **Applicant's** unique citation designation number **(optional)**. [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO SB 08B (10-01)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	09/423,100
Filing Date	December 11, 2000
First Named Inventor	Gan, Zhong-Ru
Art Unit	1647
Examiner Name	~~Saoud, Christine J.~~
Attorney Docket Number	020167-000120US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	AG	U. Shinde and M. Inouye, "Intramolecular chaperones and protein folding," *TIBS*, (1993), Vol. 18, pp. 442-446.	
	AH	M. Inouye, "Intramolecular Chaperone: The Role of the Pro-Peptide in Protein Folding," *Enzyme*, (1991), Vol. 45, pp. 314-321.	
	AI	M. Ikehara, et al., "Synthesis of a gene for human growth hormone and its expression in *Escherichia coli*," *Proc. Natl. Acad. Sci. USA*, (Oct. 1984), Vol. 81, pp. 5956-5960.	
	AJ	Watson et al., *Recombinant DNA—A Short Course*, Scientific American Books, W.H. Freeman Co., NY, (1983), pp. 231-241.	
	AK	Norman and Litwack, "Pancreatic Hormones: Insulin and Glucagon," in *Hormones*, Academic Press, Inc., NY, (1987), pp 264-317.	
	AL	I. Johnson, "Human Insulin from Recombinant DNA Technology," *Science*, (Feb. 11, 1983), Vol. 219, pp. 632-637.	
	AM	D. Williams, et al., "Cytoplasmic Inclusion Bodies in *Escherichia coli* Producing Biosynthetic Human Insulin Proteins," *Science*, (Feb. 5, 1982), Vol. 215, pp. 687-689.	
	AN	R. Burgess, "Protein Purification," in *Protein Engineering*; Oxender, D.L., Fox, C.F., Eds.; Alan R. Liss, Inc, NY, (1987), pp. 71-82.	
	AO	R.E. Chance, et al., "The Production of Human Insulin Using Recombinant DNA Technology and a New Chain Combination Procedure," in *Peptides: Synthesis-Structure-Function*, Pierce Chem. Co., Rockford, Il, (1981), pp. 721-728.	
	AP	B.H. Frank and R.E. Chance, "The Preparation and characterization of human insulin of recombinant DNA origin," in Therapeutic Agents Produced by Genetic Engineering "Quo Vadis?" Symposium, (May 29-30, 1985), Sanoff Group, Toulouse-Labège, France, pp. 137-148.	
	AQ	R.E. Chance, et al., "Chemical, Physical, and Biological Properties of Recombinant Human Insulin," in J. L. Gueriguian *Insulins, Growth Hormone, and Recombinant DNA Technology*, Raven Press, NY, (1981), pp. 71-85.	
	AR	R. D. Johnson, "The Processing of Biomacromolecules: A Challenge for the Eighties." *Fluid Phase Equilib.*, (1986), 29:109-123.	
	AS	D. V. Goeddel, et al., "Expression in *Escherichia coli* of chemically synthesized genes for human insulin," *Proc. Natl. Acad. Sci. USA*, (Jan. 1979), No. 1, pp. 106-110.	

Examiner Signature		Date Considered	2/3/2003

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional) [2] Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO SB 08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	09/423,100
Filing Date	December 11, 2000
First Named Inventor	Gan, Zhong-Ru
Art Unit	1647
Examiner Name	~~Saoud, Christine J.~~
Attorney Docket Number	020167-000120US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	AT	J. P. Burnett, "Commercial Production of Recombinant DNA-Derived Products," in *Experimental Manipulation of Gene Expression*, Academic Press, NY, (1983), pp. 259-277.	
	AU	J. Etienne-Decent, "Regulation of Protein Synthesis," in *Genetic Biochemistry: From Gene to Protein*, Ellis Horwood Limited, Chichester, U.K., (1988), pp. 125-127.	
	AV	S. M. Wheelwright, *Protein Purification: Design and Scale up of Downstream Processing*, Oxford University Press; NY, (1991), p.217.	
	AW	B.H. Frank and R.E. Chance, "Two Routes for Producing Human Insulin Utilizing Recombinant DNA Technology," *Munch. Med. Wschr.*, (1983), Vol. 125, Suppl. 1, pp. S14-S20.	
	AX	E. P. Kroeff, et al, "Production Scale Purification of Biosynthetic Human Insulin by Reversed-Phase High-Performance Liquid Chromatography," *Journal of Chromatography*, (1989), Vol. 461, pp. 45-61.	
	AY	H. V. Tottrup and S. Carlsen, "A Process for the Production of Human Proinsulin in *Saccharomyces cerevisiae*," *Biotechnol. Bioeng.*, (1990), Vol. 35, pp. 339-348.	
	AZ	L. R. Castellanos-Serra, et al., "Expression and folding of an interleukin-2-proinsulin fusion protein and its conversion into insulin by a single step enzymatic removal of the C-peptide and the N-terminal fused sequence," *FEBS Letters*, (1996), Vol. 378, pp. 171-176.	
	BA	L. Villa-Komaroff, et al., "A bacterial clone synthesizing proinsulin," *Proc. Natl. Acad. Sci. USA*, (Aug. 1978), Vol. 75, No. 8, pp. 3727-3731.	
	BB	L. Thim, et al., "Secretion and processing of insulin precursors in yeast," *Proc. Natl. Acad. Sci. USA*, (Sept. 1986), Vol. 83, pp. 6766-6770.	
	BC	I. V. Diers et al., "Yeast Fermentation Processes for Insulin Production," in Y. H. Chiu *Drug Biotechnology Regulations: Scientific Basis and Practices*, Marcel Dekker, Inc., NY, (1991), pp. 166-176.	
	BD	M. R. Ladisch and K. L. Kohlmann, "Recombinant Human Insulin," *Biotechnol. Prog.*, (1992), Vol. 8, pp. 469-478.	

Examiner Signature		Date Considered	3/6/2003

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WC 9049707 v1

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Attorney Docket No.: 20167-000120US	Application No.: 09/423,100
	Applicant: Dr. Zhong-Ru Gan	
	Filing Date: October 29, 1999	Group: ~~1798~~ 1647

Reference Designation — **U.S. PATENT DOCUMENTS** — Page 1

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
AA	6,001,604	12/14/99	Hartman et al.			
AB	4,916,212	04/10/90	Markussen et al.			
AC	4,342,832	08/03/82	Goeddel et al.			
AD	5,254,463	10/19/93	de Boer et al.			

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
AE	WO 96/20724	07/11/96	PCT			
AF	WO 97/18233	05/22/97	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER [signature] DATE CONSIDERED 3/6/2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.